finanzwire.de

Search

MAGFORCE AG (FRA:MF6) DGAP-Adhoc: MagForce AG receives FDA Investigational Device Exemption approval to conduct a clinical trial with NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

Transparency directive : regulatory news

10/02/2018 10:38

07/11/2018 10:01
24/10/2018 08:30
18/10/2018 09:30
03/09/2018 14:00
16/08/2018 10:01
09/08/2018 15:13
08/08/2018 08:25
08/08/2018 08:20
04/07/2018 14:36
02/07/2018 09:30

DGAP-Ad-hoc: MagForce AG / Key word(s): Study
MagForce AG receives FDA Investigational Device Exemption approval to conduct a clinical trial with NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

10-Feb-2018 / 10:38 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


MagForce receives FDA Investigational Device Exemption approval to conduct a clinical trial with NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

Berlin, Germany and Nevada, USA, February 10, 2018 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc., announces that it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to conduct a clinical trial with NanoTherm therapy as focal ablation treatment for intermediate risk prostate cancer.

The approval of this IDE now allows MagForce to conduct a pivotal clinical evaluation with the Company's innovative NanoTherm therapy at selected medical centers in the US. MagForce anticipates to initiate patient enrollment in this study in the coming months.

The purpose of this focal thermal ablation registration study that will enroll up to 120 men in a single arm study is to demonstrate that NanoTherm can focally ablate cancer lesions for patients who have advanced to intermediate risk prostate cancer stage and are under active surveillance. By focally ablating these cancer lesions, it is anticipated that patients will be able to be maintained in Active Surveillance Programs and to avoid definitive therapies such as surgery or whole gland radiation with their well-known side effects.

Contact:
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com


10-Feb-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

653291  10-Feb-2018 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=653291&application_name=news&site_id=symex